AstraZeneca Advances Oral GLP-1 Drug as Medicare Coverage Surge Continues
Since Medicare's Bridge program began in July 2026, approximately 700,000 seniors have enrolled in GLP-1 obesity treatments at a $50 monthly copay, with Eli Lilly products representing roughly 70 percent of enrollments. AstraZeneca has advanced its once-daily oral GLP-1 pill, elecoglipron, into Phase 3 trials, triggering a $50 million milestone payment to partner Eccogene. The new medication may not qualify for Medicare's $50 copay program and could arrive after the Bridge expires in December 2027, leaving questions about future pricing and coverage.
Medicare's Bridge program, which launched in mid-2026, has rapidly become a major access point for weight-loss medications among the elderly population. The initiative caps patient costs at $50 monthly for approved GLP-1 treatments, making these previously expensive drugs financially accessible to seniors on fixed incomes. However, this subsidized pricing structure applies only to a predetermined list of medications and operates under specific eligibility requirements established at the program's inception.
AstraZeneca's advancement of elecoglipron into Phase 3 testing represents a significant development in oral GLP-1 alternatives, as many patients prefer pill-based treatments over injectable formulations. The $50 million payment to partner Eccogene reflects the commercial significance of reaching this clinical milestone. A critical timing issue looms: the Bridge program is scheduled to expire in December 2027, potentially before elecoglipron completes trials and receives regulatory clearance.
This story could affect millions of seniors managing obesity and diabetes, as well as pharmaceutical manufacturers competing for market share in high-demand therapies. The expiration of Medicare's subsidized copay program may create significant affordability challenges for elderly patients who have become reliant on these treatments. Additionally, new oral options entering the market after the Bridge closes may face uncertain coverage decisions, potentially establishing precedent for future medication access and pricing negotiations between Medicare and pharmaceutical companies.